Concepedia

Katja M. Fagerlund

KM

Statistics

Publications

10

Citations

623

H-Index

10

Active since

2006

Affiliations

University of Turku(Current)

Pharmatest (Finland)

Katja M. Fagerlund is an author at University of Turku specializing in medicine, bone metabolism, and osteoclast biology.

Publications per year

2006–2021

10

Publications

10

Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption.

Jussi M. Halleen, Sari L Tiitinen, Hannele Ylipahkala et al. · PubMed · 2006 · 255 citations

, , +17

Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models

Mari I. Suominen, Katja M. Fagerlund, Jukka P. Rissanen et al. · Clinical Cancer Research · 2017 · 176 citations · Full text

, , +17

Survival Benefit With Radium-223 Dichloride in a Mouse Model of Breast Cancer Bone Metastasis

Mari I. Suominen, Jukka P. Rissanen, Rami S. Käkönen et al. · JNCI Journal of the National Cancer Institute · 2013 · 91 citations · Full text

, , +17

Abstract A233: Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone.

Frauke Schimmöller, Majd Zayzafoon, Leland W.K. Chung et al. · Molecular Cancer Therapeutics · 2011 · 17 citations

, , +17

Improved methods for testing antiresorptive compounds in human osteoclast cultures

Jukka P. Rissanen, Hannele Ylipahkala, Katja M. Fagerlund et al. · Journal of Bone and Mineral Metabolism · 2008 · 17 citations

, , +8

1–5 of 10